CompletedNCT07545382
Rivastigmine as an Antidote for Clozapine-induced Central Nervous System Depression and Delirium
Medication studyAges 18+Egypt
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- AlexandriaSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: December 8, 2025
- Recruitment status
- Completed
- Enrollment listed in the registry
- 100
- Sponsor
- Alexandria University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Egypt
- Age range
- Over 18 Years
- Official registry ID
- NCT07545382
- Official title
Show the full official title
Efficacy of Rivastigmine in the Management of Toxic Anticholinergic Delirium: A Prospective Study at Alexandria Poison Center
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Alexandria
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Alexandria University, a university.
Did this study involve medication?
Yes. The study involved medication, including Rivastigmine.
Who was this study for?
Listed age limits: from 18 years.
